Sponsors (5)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Introduced March 16, 2026 by James Baird · Last progress March 16, 2026
Directs the Department of Energy to create a network of at least two bioindustrial “technology maturation” facilities to help scale nonpharmaceutical biotechnology products relevant to DOE missions. It defines key terms, requires rapid planning (RFI in 90 days, strategic plan in 180 days), mandates the first facility be planned and built within two years and all facilities be operational by September 30, 2030, sets IP and data-sharing expectations, requires coordination with federal and nonfederal partners, and authorizes $225,500,000 for fiscal years 2026–2030 to support these activities.
The bill invests federal funding and coordination to create bioindustrial scale-up facilities, interoperable systems, and workforce training to speed commercialization, while shifting costs to taxpayers and risking crowding out private/local actors, IP/data exposure issues, and added administrative burdens.
Researchers, startups, and small biomanufacturers gain access to user-oriented bioindustrial maturation and scale-up facilities that enable R&D, demonstration, commercialization, and investor-ready scale validation.
Students and current tech workers will benefit from new training and workforce-development programs that build skills needed for bioindustrial manufacturing jobs.
Industry faces reduced up-front cost risk because the bill provides federal funding (up to $225.5M FY2026–2030) for planning, construction, and initial operation of scale-up facilities.
Taxpayers will bear the cost of establishing and operating the facilities, including the authorized $225.5M and potential additional appropriations or operational expenses.
Centralized federal maturation/scale-up facilities risk duplicating or crowding out private-sector investments and may disadvantage small local labs or existing manufacturers that lack access or cannot meet selection criteria.
Public-domain treatment of intellectual property created by Federal employees (or broad sharing requirements) could reduce commercialization incentives and complicate private partners' ability to capture returns on new technologies.